Related Experiment Video
Updated: Feb 12, 2026
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
Ilaria Colombo1, Stephanie Lheureux1, Amit Manulal Oza1
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Abstract:
Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability. Tumors with mutations in BRCA1/2 or other homologous recombination deficiency (HRD) genes are particularly sensitive to PARP inhibitors because of "synthetic lethality", whereby a therapeutic agent can take advantage of an intrinsic weakness in DNA repair. Rucaparib has been investigated in several preclinical and clinical studies showing promising activity in BRCA-mutant and BRCA-wild-type epithelial ovarian cancers (EOCs). Dose-escalation Phase I studies have established the recommended Phase II dose to be 600 mg twice a day for oral rucaparib. Phase II and III studies have defined its role as treatment for BRCA-mutant recurrent high-grade EOC and as maintenance treatment for platinum-sensitive relapsed EOC following response to platinum-based chemotherapy. Genomic loss of heterozygosity has also been investigated as a potential signature of HRD and as a potential predictive biomarker of response. Treatment-induced adverse events (AEs) have been observed in almost all patients treated with rucaparib, but mainly lower grade; with the most common being nausea, vomiting, asthenia/fatigue, anemia and transient transaminitis. The majority of AEs occurred early in treatment, were transient and have been easily managed with supportive treatment, dose interruption or discontinuation. This review will analyze the results of clinical trials investigating efficacy and safety of rucaparib in patients with ovarian cancer.
Insights
Rucaparib, a PARP inhibitor, shows efficacy in treating ovarian cancers, particularly those with BRCA mutations. Clinical trials confirm its role in managing recurrent and relapsed disease, with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors, like rucaparib, target DNA repair mechanisms.
- Synthetic lethality exploits DNA repair deficiencies (e.g., BRCA mutations) in tumors.
- Rucaparib demonstrates activity in epithelial ovarian cancers (EOCs) with various BRCA statuses.
Purpose of the Study:
- To review clinical trial data on rucaparib's efficacy and safety in ovarian cancer patients.
- To evaluate rucaparib's role in treating BRCA-mutant and BRCA-wild-type EOCs.
- To assess rucaparib's potential as a maintenance therapy for relapsed EOC.
Main Methods:
- Analysis of preclinical and clinical studies, including Phase I, II, and III trials.
- Investigation of rucaparib's recommended Phase II dose (600 mg twice daily).
- Exploration of genomic loss of heterozygosity as a predictive biomarker for HRD.
Main Results:
- Rucaparib is established for treating BRCA-mutant recurrent high-grade EOC.
- It serves as maintenance therapy for platinum-sensitive relapsed EOC.
- Common adverse events include nausea, fatigue, and anemia, generally manageable.
Conclusions:
- Rucaparib is an effective treatment option for specific ovarian cancer populations.
- Its safety profile is characterized by manageable, mostly early-onset adverse events.
- Further research supports rucaparib's role in ovarian cancer management.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:27Ovarian Cycle
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods
01:23Dipeptidyl Peptidase 4 Inhibitors
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...